Please login to the form below

Not currently logged in
Email:
Password:

GSK and Concert collaborate on novel drugs

Concert Pharmaceuticals and GSK are to collaborate on the development and commercialisation of deuterium-containing medicines

Concert Pharmaceuticals and GlaxoSmithKline (GSK) are to collaborate on the development and commercialisation of deuterium-containing medicines. The deal covers three of Concert's research and development programmes: CTP-518, a protease inhibitor for the treatment of HIV expected to enter phase I clinical trials in the second half of 2009; a preclinical compound for chronic renal disease, and a third research product in Concert's pipeline. Concert will also provide GSK with deuterium-modified versions of three GSK pipeline compounds for GSK to develop.

Under the terms of the agreement, Concert will receive $35m at the start, including a $16.7m equity investment by GSK. Concert is eligible to receive milestones and tiered royalties based on deuterium-containing products arising from the Concert pipeline programmes. In addition, Concert is eligible to receive milestones and royalties on the sales of deuterium-containing products arising from the GSK pipeline compounds. Overall, Concert could potentially receive in excess of $1bn in total.

For each Concert pipeline programme, Concert will have responsibility for R&D activities through completion of pre-agreed clinical trials. After the completion of trials for each programme, or earlier, GSK may elect to obtain an exclusive, worldwide licence to product candidates in the programme and assume responsibility for development and commercialisation. Concert will retain full rights to further develop and commercialise its product candidates in any programme GSK chooses not to license.

"This agreement marks GSK's continued efforts to access the best science and technology platforms worldwide," said Patrick Vallance, senior vice-president drug discovery at GSK. "We believe Concert's approach to deuterium modification of medicines has broad potential to enhance certain drug properties and result in innovative new medicines."

"We are pleased to collaborate with GSK and to advance innovative small molecule drug candidates using our deuterium chemistry approach," said Dr Roger Tung, president and chief executive officer of Concert Pharmaceuticals. 

3rd June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics